spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  REYATAZ 

 HSMN NewsFeed - 22 Jun 2017
Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Apr 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2015
Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 12 Dec 2013
VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Jun 2013
VIVUS Announces SPEDRA (avanafil) Approval in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 May 2013
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA(R) (efavirenz) in HIV-1 Infected Pediatric Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 3 May 2011
Optimer Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 24 Jun 2008
European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naïve HIV-1 Infected Adults
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 15 Nov 2007
Significant Changes in Store for Growing HIV Market
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 25 Jul 2007
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 17 May 2007
Health Canada approves REYATAZ(R) (atazanavir sulfate) 300 mg single capsule formulation in combination therapy for adults with HIV-1 infection
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 14 Nov 2006
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2006
Panacos Appoints Scott McCallister, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2006
FDA Approves REYATAZ(R) (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
Biopharmaceuticals HIV/AIDS FDA
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
REYATAZ
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.